76 related articles for article (PubMed ID: 2843483)
21. Systemic and topical protection studies using Pseudomonas aeruginosa flagella in an ocular model of infection.
Rudner XL; Hazlett LD; Berk RS
Curr Eye Res; 1992 Aug; 11(8):727-38. PubMed ID: 1424719
[TBL] [Abstract][Full Text] [Related]
22. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice.
Sokalska M; Maresz-Babczyszyn J
Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542
[TBL] [Abstract][Full Text] [Related]
23. Evidence for N-acetylmannosamine as an ocular receptor for P. aeruginosa adherence to scarified cornea.
Hazlett LD; Moon MM; Strejc M; Berk RS
Invest Ophthalmol Vis Sci; 1987 Dec; 28(12):1978-85. PubMed ID: 3119512
[TBL] [Abstract][Full Text] [Related]
24. Further studies on the role of IL-12 in Pseudomonas aeruginosa corneal infection.
Hazlett LD; Huang X; McClellan SA; Barrett RP
Eye (Lond); 2003 Nov; 17(8):863-71. PubMed ID: 14631390
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.
Hancock RE; Mutharia LM; Mouat EC
Eur J Clin Microbiol; 1985 Apr; 4(2):224-7. PubMed ID: 2408887
[TBL] [Abstract][Full Text] [Related]
26. Characterization of two surface-localized antigenic sites on porin protein F of Pseudomonas aeruginosa.
Mutharia LM; Hancock RE
Can J Microbiol; 1985 Apr; 31(4):381-6. PubMed ID: 2408719
[TBL] [Abstract][Full Text] [Related]
27. Anti-receptor antibodies inhibit Pseudomonas aeruginosa binding to the cornea and prevent corneal perforation.
Hobden JA; Gupta SK; Masinick SA; Wu X; Kernacki KA; Berk RS; Hazlett LD
Immunol Cell Biol; 1996 Jun; 74(3):258-64. PubMed ID: 8799726
[TBL] [Abstract][Full Text] [Related]
28. Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.
Rahner R; Eckhardt A; Duchêne M; Domdey H; von Specht BU
Infection; 1990; 18(4):242-5. PubMed ID: 2120132
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of protective mAbs against Pseudomonas aeruginosa outer membrane protein I by C1q binding assay.
Eckhardt A; Heiss MM; Ehret W; Permanetter W; Duchêne M; Domdey H; von Specht BU
Zentralbl Bakteriol; 1991 Apr; 275(1):100-11. PubMed ID: 1930557
[TBL] [Abstract][Full Text] [Related]
30. Pseudomonas eye infections in cyclophosphamide-treated mice.
Hazlett LD; Rosen DD; Berk RS
Invest Ophthalmol Vis Sci; 1977 Jul; 16(7):649-52. PubMed ID: 873724
[TBL] [Abstract][Full Text] [Related]
31. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.
von Specht BU; Knapp B; Muth G; Bröker M; Hungerer KD; Diehl KD; Massarrat K; Seemann A; Domdey H
Infect Immun; 1995 May; 63(5):1855-62. PubMed ID: 7729895
[TBL] [Abstract][Full Text] [Related]
32. Evidence for asialo GM1 as a corneal glycolipid receptor for Pseudomonas aeruginosa adhesion.
Hazlett LD; Masinick S; Barrett R; Rosol K
Infect Immun; 1993 Dec; 61(12):5164-73. PubMed ID: 8225593
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic and therapeutic vaccine against Pseudomonas aeruginosa keratitis using bacterial membrane vesicles.
Ito S; Nakamura J; Fukuta M; Ura T; Teshigawara T; Fukushima J; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 May; 39(23):3152-3160. PubMed ID: 33934918
[TBL] [Abstract][Full Text] [Related]
34. [Generation and protective activities of human monoclonal antibodies against Pseudomonas aeruginosa].
Sawada S; Kawamura T
Nihon Rinsho; 1991 Oct; 49(10):2441-5. PubMed ID: 1749101
[No Abstract] [Full Text] [Related]
35. Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.
Gilleland HE; Parker MG; Matthews JM; Berg RD
Infect Immun; 1984 Apr; 44(1):49-54. PubMed ID: 6323316
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies.
Lang AB; Fürer E; Cryz SJ
FEMS Immunol Med Microbiol; 1993 Jun; 7(1):9-13. PubMed ID: 8364527
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic and therapeutic efficacy of a fully human immunoglobulin G1 monoclonal antibody to Pseudomonas aeruginosa alginate in murine keratitis infection.
Zaidi T; Pier GB
Infect Immun; 2008 Oct; 76(10):4720-5. PubMed ID: 18644881
[TBL] [Abstract][Full Text] [Related]
38. [Immunobiological properties of recombinant L peptide from the Pseudomonas aeruginosa outer membrane].
Gatypova EV; Zlygostev SA; Kaloshin AA; Mikhaĭlova NA
Vestn Ross Akad Med Nauk; 2009; (4):25-8. PubMed ID: 19514308
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of Pseudomonas aeruginosa ocular diseases.
Kreger AS
Rev Infect Dis; 1983; 5 Suppl 5():S931-5. PubMed ID: 6419316
[TBL] [Abstract][Full Text] [Related]
40. Rabbit corneal damage produced by Pseudomonas aeruginosa infection.
Gray LD; Kreger AS
Infect Immun; 1975 Aug; 12(2):419-32. PubMed ID: 169202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
